Women With Previously Treated Advanced Breast Cancer Benefit From Addition Of Everoli
 

The mammalian target of rapamycin (mTOR) inhibitor everolimus given with the aromatase inhibitor exemestane markedly boosts progression-free survival (PFS) in post-menopausal women with advanced breast cancer compared with hormonal therapy alone, according to updated results of the phase III Breast Cancer Trials of Oral Everolimus (BOLERO)-2 study reported at the 34th Annual S...

More...